에임드바이오 Stock: price and insider trades · South Korea

This page follows insider dealings at 에임드바이오 as filed with DART (FSS), a company from the Health Care sector. 11 insiders have disclosed 19 filings since 1 November 2025.

Open-market activity splits into 13 purchases and 5 sales totalling €69.0M; 10 insiders sit on the buying side and 2 insiders on the selling side. No amount is published for 17 filings, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The largest single trade was a sale of €69.0M by 인터베스트, published on 17 March 2026. The buyers include 3 senior executives, 2 board members and 1 major shareholder.

With 19 filings in twelve months, the company is more active than the median of 7 filings across the 2,655 companies we follow on the same exchange. Over the whole record (from 2025), the tally stands at 13 purchases and 5 sales.

The last insider purchase was made public on 18 September 2026, 53 days ago. Typically, a trade is published a median of 6 days after it takes place. This delay matters because a trade only becomes useful information once it is public.

For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and UCB. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.